AET has been the subject of a number of other recent research reports. Analysts at Barclays Capital (NYSE: BCS) reiterated an “overweight” rating on shares of Aetna in a research note to investors on Tuesday. Separately, analysts at Goldman Sachs (NYSE: GS) downgraded shares of Aetna from a “neutral” rating to a “sell” rating in a research note to investors on Wednesday, May 9th. They now have a $45.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Aetna from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, May 2nd. They now have a $47.00 price target on the stock.
Shares of Aetna traded down 0.22% during mid-day trading on Wednesday, hitting $40.12. Aetna has a 52 week low of $33.43 and a 52 week high of $51.14. The company has a market cap of $13.938 billion and a P/E ratio of 7.83.
Aetna last released its earnings data on Thursday, April 26th. The company reported $1.34 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.39 by $0.05. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Analysts expect that Aetna will post $1.34 EPS next quarter.
Aetna Inc. (Aetna) is a diversified health care benefits company, serving approximately 35.3 million people.